Journal articleJ Clin Oncol2014
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
- Journal
- J Clin Oncol
- Published
- 30 June 2014
- Citations
- 336
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 3
- Builds on itA Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003 NCT00786058↗
- BackgroundTAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma NCT04923529↗
- BackgroundSecond-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer NCT02558868↗